Literature DB >> 22357779

Cluster analysis of symptoms in pulmonary arterial hypertension: a pilot study.

Lea Ann Matura1, Annette McDonough, Diane L Carroll.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary artery pressures leading to right heart failure and death. AIMS: The aim of this study was to use cluster analysis to describe the symptom profile in PAH and differences in the health outcomes of health status, health-related quality of life (HRQoL) and psychological states in the cluster groups.
METHODS: A cross-sectional descriptive design was used. A convenience sample completed a socio-demographic and clinical data form, a PAH Symptom Severity and Interference Scale, the Medical Outcomes Study Short Form (SF-36), the United States Cambridge Pulmonary Hypertension Outcome Review (US CAMPHOR) and the Short Form of the Profile of Mood States (POMS).
RESULTS: Of the 151 participants, the mean age was 53.5 ± 15.1 with the majority female (n = 128, 85%). Fifty-eight (41%) were disabled and 67 (44%) were Functional Class IV. The most prevalent symptoms were shortness of breath with exertion (n = 149, 99%) and fatigue (n = 144, 93%). Three clusters emerged: Cluster 1 diffuse symptoms (n = 93), Cluster 2 severe cardiopulmonary symptoms (n = 32) and Cluster 3 moderate cardiopulmonary symptoms (n = 26). Overall, on the SF-36 the participants had poor general health, reduced physical function, role physical, vitality, and a low composite score for physical health. On the POMS the sample had limited vigor and increased fatigue. Cluster 2 Severe Cardiopulmonary Symptoms had worse SF-36, US CAMPHOR and POMS scores than the other cluster groups.
CONCLUSIONS: Patients with PAH are experiencing a constellation of symptoms that are interfering with their life and emerging clusters were present.

Entities:  

Mesh:

Year:  2012        PMID: 22357779     DOI: 10.1177/1474515111429649

Source DB:  PubMed          Journal:  Eur J Cardiovasc Nurs        ISSN: 1474-5151            Impact factor:   3.908


  17 in total

1.  Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey.

Authors:  Eric R Fenstad; Tait D Shanafelt; Jeff A Sloan; Paul J Novotny; Louise A Durst; Robert P Frantz; Michael D McGoon; Keith M Swetz
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

2.  Slow-paced respiration therapy to treat symptoms in pulmonary arterial hypertension.

Authors:  Lea Ann Matura; Jamison Fargo; Jason S Fritz; Kerri A Smith; Anjali Vaidya; Diane Pinder; Christine Archer-Chicko; Harold I Palevsky; Allan I Pack; Marilyn S Sommers; Steven M Kawut
Journal:  Heart Lung       Date:  2016-11-22       Impact factor: 2.210

3.  Physical Activity and Symptoms in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Haochang Shou; Jason S Fritz; K Akaya Smith; Anjali Vaidya; Diane Pinder; Christine Archer-Chicko; Danielle Dubow; Harold I Palevsky; Marilyn S Sommers; Steven M Kawut
Journal:  Chest       Date:  2016-02-15       Impact factor: 9.410

4.  An Update on Pulmonary Arterial Hypertension.

Authors:  Joanna Wapner; Lea Ann Matura
Journal:  J Nurse Pract       Date:  2015-05       Impact factor: 0.767

5.  Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.

Authors:  Lea Ann Matura; Corey E Ventetuolo; Harold I Palevsky; David J Lederer; Evelyn M Horn; Stephen C Mathai; Diane Pinder; Christine Archer-Chicko; Emilia Bagiella; Kari E Roberts; Russell P Tracy; Paul M Hassoun; Reda E Girgis; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2015-03

Review 6.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

7.  Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension.

Authors:  Ali A Weinstein; Lisa M K Chin; Randall E Keyser; Michelle Kennedy; Steven D Nathan; Joshua G Woolstenhulme; Gerilynn Connors; Leighton Chan
Journal:  Respir Med       Date:  2013-03-07       Impact factor: 3.415

Review 8.  Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.

Authors:  Carl P Walther; Vijay Nambi; Nicola A Hanania; Sankar D Navaneethan
Journal:  Am J Kidney Dis       Date:  2020-03-19       Impact factor: 8.860

9.  Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  J Pain Symptom Manage       Date:  2015-08-20       Impact factor: 3.612

10.  Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.

Authors:  James Twiss; Stephen McKenna; Louise Ganderton; Sue Jenkins; Mitra Ben-L'amri; Kevin Gain; Robin Fowler; Eli Gabbay
Journal:  BMC Pulm Med       Date:  2013-07-12       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.